BioSpace News Archive

Mirati Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common stock at a public offering price of $202.00 per share, which consists of 4,585,706 shares sold by Mirati and 400,000 shares sold by a selling stockholder.

Xeris Pharmaceuticals, Inc. announced that on October 28, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 36,250 share of its common stock to 15 new employee under Xeris’ Inducement Equity Plan.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that management will present a company update at the following virtual investor conferences:

Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020, before the market opens.

Icosavax, Inc. today announced the launch of the company’s COVID-19 vaccine program with preclinical data on the company’s VLP vaccine candidate, IVX-411, which comprises a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain (RBD) in a highly immunogenic array.